Strides Pharma Science Ltd. posted a robust 81% year-on-year jump in its consolidated profit after tax (PAT) for the first quarter of FY26, reaching Rs. 114 crore. The growth was powered by sustained momentum in the U.S. generics business, improved operational efficiencies, and a healthier product mix. Revenues rose 9% to Rs. 1,136 crore, while the company’s core earnings before interest, tax, depreciation, and amortization (EBITDA) rose by 27%.